Logo

WGRX

Wellgistics Health, Inc.

WGRX

Wellgistics Health, Inc. • NASDAQ
$0.60 ▼ -5.00% (-0.03)
Market Cap $42.00 M
52w High $7.04
52w Low $0.34
Dividend Yield 0%
P/E -0.47
Volume 554.66K
Outstanding Shares 69.99M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $3.013M ▼ $30.977M ▲ $-34.318M ▼ -1.139K% ▼ $-0.46 ▼ $-30.746M ▼
Q2-2025 $7.791M ▼ $6.006M ▼ $-6.672M ▲ -85.645% ▲ $-0.11 ▲ $-4.686M ▲
Q1-2025 $10.863M ▲ $32.041M ▲ $-32.431M ▼ -298.532% ▼ $-0.62 ▼ $-30.534M ▼
Q4-2024 $-16.048M ▼ $-1.728M ▼ $355.285K ▲ -2.214% ▲ $-0.083 ▼ $659.204K ▲
Q3-2024 $15.801M $3.651M $-3.054M -19.325% $-0.036 $-1.508M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $4.229M ▲ $52.78M ▼ $46.002M ▼ $6.778M ▲
Q2-2025 $419.942K ▼ $54.225M ▼ $53.32M ▼ $905.255K ▼
Q1-2025 $2.517M ▲ $58.063M ▲ $53.584M ▲ $4.479M ▼
Q4-2024 $1.028M ▲ $57.333M ▲ $50.598M ▲ $6.734M ▼
Q3-2024 $793.148K $55.572M $45.586M $9.985M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-34.318M ▼ $-1.135M ▲ $-221.085K ▼ $5.165M ▲ $3.809M ▲ $-730.27K ▲
Q2-2025 $-6.672M ▲ $-2.079M ▼ $-131.926K ▲ $114.281K ▼ $-2.097M ▼ $-2.211M ▼
Q1-2025 $-32.431M ▼ $-1.347M ▲ $-273.133K ▼ $3.109M ▲ $1.488M ▲ $-1.621M ▲
Q4-2024 $-4.332M ▼ $-2.66M ▼ $838.409K ▲ $2.056M ▲ $235.188K ▼ $-2.772M ▼
Q3-2024 $-1.867M $1.326M $-315.937K $-283.518K $726.173K $1.109M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025
Product
Product
 $10.00M ▲$10.00M ▲$0 ▼

Five-Year Company Overview

Income Statement

Income Statement Wellgistics looks very early-stage from an income perspective. Revenue has been minimal and inconsistent, and the business is still posting losses. The trend in per‑share losses suggests expenses to build the platform and network are rising faster than revenue is coming in. In plain terms, they are in “build mode,” not “earnings mode.” The story is about investing ahead of scale, with profitability still clearly in the future rather than visible in the recent numbers.

Balance Sheet

Balance Sheet The balance sheet is small and quite thin. Assets are limited, there is little reported cash, and there is already some debt relative to a modest equity base. That means the financial cushion is not large. This kind of structure is typical for a young, fast‑building company, but it also means the business is sensitive to setbacks and likely needs continued access to outside capital, including from its IPO and other financings, to support growth and cover operating losses.

Cash Flow

Cash Flow The reported cash flow figures are effectively flat, which likely reflects limited operating scale and early-stage reporting rather than strong cash generation. There is no sign yet of meaningful cash inflow from the core business. In practice, a company at this stage is almost certainly using cash to fund operations, technology development, and network expansion. The key future watch-points will be how quickly operating cash outflows stabilize, when the business begins to generate cash from operations, and whether they can fund that journey without undue strain from new debt or constant equity issuance.

Competitive Edge

Competitive Edge Competitively, Wellgistics is trying to carve out a niche between traditional drug distributors and pure software platforms. Its focus on independent pharmacies, combined with tech tools for routing prescriptions and managing hub services, gives it a differentiated positioning versus the large, integrated giants that dominate U.S. drug distribution and PBM services. The potential strength lies in network effects: the more pharmacies, manufacturers, and payers on the platform, the more useful and sticky it becomes. However, this market is crowded, heavily regulated, and dominated by very large incumbents with deep relationships. Wellgistics’ PBM‑agnostic, transparency‑focused model is a clear angle, but it still needs to prove it can scale, win trust, and maintain margins in a tough competitive landscape.

Innovation and R&D

Innovation and R&D Innovation is the center of the Wellgistics story. The company is building an ecosystem of AI and digital tools—EinsteinRx for prescription optimization, HubRx AI for automating hub services, a blockchain layer for secure tracking, and a marketplace for price transparency. Together, these aim to streamline the path from manufacturer to patient and reduce friction for pharmacies and prescribers. They are also experimenting with niche offerings like “specialty lite” products, medical foods tied to GLP‑1 use, financial tools for pharmacies, and unconventional marketing and partnership strategies. The opportunity is that technology plus services could create a high‑value, defensible platform. The risk is execution: integrating all these pieces, driving real adoption, and turning innovation into recurring, profitable revenue is still unproven at this stage.

Summary

Wellgistics Health is essentially a pharma‑tech infrastructure play in its infancy: the financials show a tiny, loss‑making business, while the narrative describes an ambitious platform trying to rewire how prescriptions flow through the U.S. system. On the positive side, the company has a clear vision—blend AI, blockchain, and digital routing with a physical pharmacy network to increase transparency and efficiency, particularly for independent pharmacies. That creates potential for network effects and differentiated services in a sector that many stakeholders find frustrating and opaque. On the risk side, the current business base is very small, profitability is not yet in sight, and the balance sheet appears thin, suggesting reliance on ongoing external funding. The competitive field is intense, regulatory and operational complexity is high, and many of the touted innovations need real-world adoption and monetization to validate the model. Overall, this looks like a high-innovation, high-execution-risk story where the long-term outcome will depend on scaling the network, proving the technology in everyday use, and building a stable, cash-generating business on top of the current early-stage platform.

NEWS

November 26, 2025 · 7:45 AM UTC

Wellgistics Health Announces Sponsorship of Dream Bowl 2026 and Participation in DataVault AI Dream Bowl 2026 Meme Coin Shareholder Distribution Plan

Read more

November 20, 2025 · 6:00 AM UTC

Wellgistics Health Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 17, 2025 · 6:00 AM UTC

Wellgistics Health to Report Third Quarter 2025 Financial Results and Provide a Business Update on the morning of Thursday, November 20th, 2025

Read more

November 14, 2025 · 9:00 AM UTC

Wellgistics Health to Distribute Tollo Health GLP-1 Companion Muscle Loss Medical Food to Pharmacies & Physicians

Read more

November 12, 2025 · 7:40 AM UTC

Wellgistics Health Launches EinsteinRx as the Premier AI Prescription Management Hub Solution to Integrate Physical and Technology Healthcare Infrastructure

Read more